MS Tied to Increased Risk of Life-limiting Issues & Immunotherapy, Aubagio and Other MS News.
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how MS can increase the risk of potentially life-limiting problems like pneumonia, as a team of scientists in the U.S....
24 Kesä 202210min
Jenn Talks to Author With MS, Dr. Annie Brewster
Annie Brewster is an assistant professor of medicine at Harvard Medical School, a practicing physician at Massachusetts General Hospital in Boston, and the founder and executive director of Health Sto...
23 Kesä 202232min
Evusheld Boosts COVID-19 Antibodies Post-vaccination & Pain Management for People With MS
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discuses how Evusheld was found to boost immune responses against COVID-19 among vaccinated multiple sclerosis patients. He also...
22 Kesä 202217min
Trial Is Testing Cutting-edge Immunotherapy in MS Patients & Making the Most of Limited Energy
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how a phase 1/2 clinical trial is evaluating the safety and effectiveness of a cutting-edge immunotherapy called extra...
20 Kesä 20229min
Pandemic’s Negative Aspects Tied to Worse Disability & A Weekend Out, With MS
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads a news article about how the pandemic’s negative aspects were associated with worse MS disability in patients living in It...
17 Kesä 202210min
#31DaysOfMS - Facebook Live with Rennie Rankin and Melody Sapien
Follow us on social media! Instagram - https://www.instagram.com/msnewstoday/ Twitter - https://twitter.com/MSNewsToday Facebook - https://www.facebook.com/multiplesclerosisnewstoday/ Our #31DaysOfMS...
16 Kesä 202242min
No Disease Activity on Aubagio After 2 Years & A Road Trip With No Bladder Incontinence
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, explains how more than half of multiple sclerosis patients on Aubagio showed no evidence of disease activity after two years, ac...
15 Kesä 20228min
Ponvory Reduces Risk of Worsening Disability & Managing Tomorrow’s Consequences
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads a news article on the effectiveness of Ponvory that has emerged from analyzing a database of multiple sclerosis clinical t...
13 Kesä 20228min
